Antibacterial peptides for therapeutic use: obstacles and realistic outlook.

By A. Marr, W. J. Gooderham, Robert E. W. Hancock. Current opinion in pharmacology (Print), 2006

1,031 citations recorded by the source corpus.

Subfields: Microbiology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/dee714f9de0c2320bc36d6f36a2e4478eb334b8c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Microbiology

In Molecular Biology

Citations in the corpus

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents (2016, background): “Many AMPs exhibit an extraordinarily broad range of antimicrobial activity covering both Gram-positive and Gram-negative bacteria as well as fungi, viruses, and unicellular protozoa (Hancock and Diamond, 2000; Reddy et al., 2004; Marr et al., 2006).”
Antimicrobial peptides: The ancient arm of the human immune system (2010, background): “However, the FDA rejected the approval of pexiganan in 1999, reportedly as it did not offer any great advantage over the current standard of care.(28) Omiganan derived from bovine indolicidin.”
Antimicrobial peptides: key components of the innate immune system (2012, background): “For treating a single patient with an infection, one may need up to mg amounts per kg body weight per day, and production alone of such a quantity through chemical synthesis will cost around 5–300 US $, far exceeding current costs for antibiotics (Marr et al., 2006).”
Multifunctional cationic host defence peptides and their clinical applications (2011, background): “To date, more than 1,000 natural cationic peptides with antimicrobial properties have been identified, often with broad-spectrum activity against Gram-negative and Gram-positive bacteria, viruses, protozoa, and/or fungi [62].”
Antimicrobial peptides: an overview of a promising class of therapeutics (2007, background): “As a typical example, for the treatment of infections with the currently known AMPs about 1 mg/kg of body weight per day per patient would be necessary, with a cost of about $50-400 per gram [104] far too expensive for everyday usage in less developed countries.”
Antimicrobial Peptides (2013, background): “Despite these advantageous features of AMPs, there are still some challenges to their applications, such as potential toxicity to humans [12,55,56], sensitivity to harsh environmental conditions (susceptibility to proteases and extreme pH [57,58]), lack of selectivity against specific strains [59], ”